ResearcherFujian Medical UniversityNo recent work listed

Yangyang Dong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1142-9131; OpenAlex author ID A5001549076. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper

Papers 2

Overexpressing PRMT1 Inhibits Proliferation and Invasion in Pancreatic Cancer by Inverse Correlation of ZEB1. Last author DOI 10.1002/iub.1917 ↗
The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo. Co-author DOI 10.1007/s13277-016-5403-5 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zhibin Lin · 1 shared paper, 2018 · strength 0.11
- Paper Overexpressing PRMT1 Inhibits Proliferation and Invasion in Pancreatic Cancer by Inverse Correlation of ZEB1. DOI 10.1002/iub.1917 ↗
Wenbing Zou · 1 shared paper, 2016 · strength 0.08
- Paper The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo. DOI 10.1007/s13277-016-5403-5 ↗
Yan Liu · 1 shared paper, 2016 · strength 0.08
- Paper The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo. DOI 10.1007/s13277-016-5403-5 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.